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ABSTRACT
CHARACTERIZATION OF METALLOTHIONEIN EXPRESSION IN
RESPONSE TO CADMIUM IN THE 267-B1, NORMAL PROSTATE
CELL LINE
Madhuri G. Neriyanuri
The objective of the study was to characterize the mRNA and protein expression of the
MT gene in response to Cd2+ exposure in the 267-B1 immortalized normal human
neonatal prostate cell line. The cells were exposed to 18µM Cd2+ for 4hr and rescued for
48hr in P4-8F normal medium. Samples were obtained at 0, 1, 2, 4hr exposure and 4, 8,
12, 16, 24, 36, and 48hr recovery. Basal levels of mRNA for MT-1E, MT-1X, and MT2A genes in 267-B1 cells were similar to the expression of the G3PDH where as MT-3
had a low basal level expression. Exposure to Cd2+ following recovery in normal medium
showed the expression of MT-1A, MT-1F, MT-1G genes and a 3 fold induction of MT1E and a lesser induction of MT-1X and MT-2A. The basal level of MT-1/2 protein was
found to be 3.2±0.17 ng MT/total protein with levels gradually increasing as a result of
Cd2+ exposure. No MT-3 protein was induced on exposure to Cd2+.

ACKNOWLEDGEMENTS
First, I would like to thank Dr. Donald A. Sens, for giving me the opportunity to work in
his lab. Dr. Scott H. Garrett for his continuous guidance and patience in helping me in
every aspect of this work. Dr. Seema Somji, who first taught me the techniques in the
laboratory. Dr. Joginder Nath for giving me the opportunity to be a student and guiding
me through the graduate program. I would also like to thank my friends in the lab who
helped me in so many other ways.
Most importantly, I would like to thank my parents and brothers for supporting me and
being the inspiration for doing higher studies. I would like to make special thanks to my
husband, for constantly encouraging and supporting me in the completion of my Master's
program. Without his support and love, this would not have been possible.

iii

TABLE OF CONTENTS
CHARACTERIZATION OF METALLOTHIONEIN EXPRESSION IN RESPONSE TO
CADMIUM IN THE 267-B1, NORMAL PROSTATE CELL LINE ................................. i
ABSTRACT........................................................................................................................ ii
ACKNOWLEDGEMENTS............................................................................................... iii
TABLE OF CONTENTS................................................................................................... iv
TABLE OF FIGURES........................................................................................................ v
INTRODUCTION .............................................................................................................. 1
FUNCTION OF MT ....................................................................................................... 2
MT IN CELL PROLIFERATION AND APOPTOSIS .............................................. 2
HOMEOSTASIS OF ESSENTIAL METALS ........................................................... 4
MT AS FREE RADICAL SCAVENGER.................................................................. 5
ROLE OF MT IN METAL DETOXIFICATION ...................................................... 6
MT EXPRESSION IN CANCER................................................................................... 7
EXPRESSION IN THE PROSTATE ............................................................................. 8
MT1/2 IN THE PROSTATE ...................................................................................... 8
MT-3 IN THE PROSTATE ...................................................................................... 10
267-B1 NORMAL NEONATAL HUMAN PROSTATE CELL LINE ....................... 12
MATERIALS AND METHODS...................................................................................... 13
CELL CULTURE REAGENTS ................................................................................... 13
267-B1 CELL LINE ................................................................................................. 13
P4-8F SERUM FREE MEDIUM.............................................................................. 13
PHOSPHATE BUFFERED SALINE (1X PBS) ...................................................... 13
267-B1 CELL CULTURE ............................................................................................ 14
CELL GROWTH .......................................................................................................... 15
CADMIUM EXPOSURE & RECOVERY .................................................................. 15
SET UP ..................................................................................................................... 15
TOTAL RNA ISOLATION AND RT-PCR ................................................................. 16
RNA ISOLATION PROTOCOL.............................................................................. 16
RNA QUANTITATION BY SPECTROPHOTOMETER....................................... 17
RT-PCR..................................................................................................................... 17
PROTEIN EXTRACTION ........................................................................................... 19
PROTEIN QUANTITATION ...................................................................................... 19
THE ELISA TOTAL PROTEIN ASSAY USING THE BCA COPPER
REDUCTION METHOD ......................................................................................... 19
MT PROTEIN DETERMINATION............................................................................. 20
RESULTS ......................................................................................................................... 22
267-B1 CELL GROWTH ............................................................................................. 22
MT-mRNA AND PROTEIN EXPRESSION IN THE 267-B1 CELL LINE............... 22
DISCUSSION ................................................................................................................... 37
APPENDIX....................................................................................................................... 41
REAGENTS USED FOR PROTEIN CELL EXTRACTS........................................... 41
REFERENCES ................................................................................................................. 43
VITA ................................................................................................................................. 49

iv

TABLE OF FIGURES
Figure 1 Phase-contrast photomicrograph of 267-B1 cells. Confluent monolayer of 267B1 normal neonatal prostate cells maintained in P4-8F serum-free growth medium.
................................................................................................................................... 26
Figure 2 Growth curve of 267-B1 cells. Confluent monolayer of 267-B1 normal neonatal
prostate cells maintained in P4-8F serum-free growth medium. .............................. 27
Figure 3 Basal MT gene expression determined by RT-PCR using total RNA from 267B1 cells. Total RNA was purified from the 267-B1 cells and subjected to RT-PCR
using primers specific for G3PDH, MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT1H, MT-1X, MT-2A, MT-3, and MT-4. The reactions were sampled at 25, 30, 35,
40 cycles and the products visualized on 2% agarose gel containing 0.25µg per ml
ethidium bromide. ..................................................................................................... 28
Figure 4 Expression of MT-1A in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1A (40 cycles). Gel shows gene expression at various time points during
exposure and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for
MT-1A gene expression............................................................................................ 29
Figure 5 Expression of MT-1E in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1E (30 cycles). Gel shows gene expression at various time points during
exposure and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for
MT-1E gene expression. ........................................................................................... 30
Figure 6 Expression of MT-1F in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1F (40 cycles). Gel shows gene expression at various time points during
exposure and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for
MT-1F gene expression. ........................................................................................... 31
Figure 7 Expression of MT-1G in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1G (40 cycles). Gel shows gene expression at various time points during
exposure and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for
MT-1G gene expression............................................................................................ 32
Figure 8 Expression of MT-1X in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1X (40 cycles). Gel shows gene expression at various time points during
exposure and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for
MT-1X gene expression............................................................................................ 33

v

Figure 9 Expression of MT-2A in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-2A (25 cycles). Gel shows gene expression at various time points during
exposure and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for
MT-2A gene expression............................................................................................ 34
Figure 10 Expression of MT-3 in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-3 (40 cycles). Gel shows gene expression at various time points during
exposure and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for
MT-3 gene expression............................................................................................... 35
Figure 11 Expression of MT-1/2 protein in 267-B1 cell line maintained in serum-free
growth medium following exposure to 18mM cadmium for four hours. IOD of
bands represent MT1/2 protein. ................................................................................ 36

vi

INTRODUCTION
Metallothioneins (MT) are low molecular (6-7kDa), cysteine-rich, metal binding
proteins (1). MT was first identified as a cadmium binding protein in equine kidney in
1957 and was subsequently purified and characterized by Kagi and Vallee (2). MT is
characterized by its low molecular weight, high metal content, characteristic amino acid
composition (high content of conserved cysteine residues and absence of aromatic amino
acids) spectroscopic features indicating tetrahedral–thiolate complexes and metal thiolate
clusters (3).
Based on their structural similarities MTs have been divided into 4 classes; MT-1
and MT-2, two ubiquitously expressed, heavy metal binding proteins, expressed in all
eukaryotes including plants, yeast, worms, flies and some vertebrates. MT-3 was initially
detected as the factor deficient in the brain of patients with Alzheimer’s disease that
inhibited neuronal cell growth in culture (4). It is predominantly expressed in
glutaminergic neurons of the brain (5). MT-4 is expressed in the stratified squamous
epithelium of skin, tongue and intestinal lining and appears to play an important role in
the differentiation of these tissues (6).
MTs have two globular metal binding domains, α (in the C terminal region) and β
(in the N-terminal region), that are conserved among all four isoforms. MT-3 contains an
additional C terminal hexapeptide and proline residues at position 7 and 9 that probably
impart its growth inhibitory properties to neuronal cells in culture (7). The structures of
all four isoforms are highly conserved at the amino acid and nucleotide levels.
Human MT genes are clustered at a single locus on chromosome 16 (16q13) (8) and at
least 10 of the 17 genes so far identified, are functional. These encoded multiple isoforms
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of MT-1 and, usually, a single form of MT-2 (9). Only single genes for MT-3 and MT-4
have been detected. The expression and the gene sequence of the functional genes have
been reported for MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1H, MT-1X, MT-2A,
MT-3, and MT-4, the non-functional MT genes are MT-1C, MT-1D, MT-1I, MT-1J, MT1K, MT-1L and MT-2B (3). MT-3 is preferentially expressed in the brain (5), although
recently it has been detected in the maternal decidium, reproductive tissues, as well as the
kidney (10, 11). The MT-4 gene from mouse and human has been cloned and the
expression of the gene appears to be limited to squamous epithelial cells (6).

FUNCTION OF MT
MT has a relatively rapid rate of turnover and this has been taken as evidence for
a regulatory function. Detailed analysis of the structure of MT has been helpful in
delineating some of the possible biological roles for this protein. The metal thiolate
clusters within the MT molecules allow rapid exchanges of metal ions between clusters
and with other MT molecules (3). Hence, it is thought that this characteristic, which
appears to be unique to MT, aids the transfer of metal ions and is fundamental to its
biological role (12). Functions of MTs include metal absorption/excretion, metal
detoxification, apoptosis, and modulation of the intracellular redox balance.
MT IN CELL PROLIFERATION AND APOPTOSIS
A number of investigations suggest that MT plays an important role in cell
proliferation. For instance, in mammals high levels of MT expression have been detected
during later stages of gestation and neonatal periods (3); MT levels are also transiently
elevated during liver regeneration as well as in liver and kidney of uninephrectomized
rats. Increased MT levels have also been reported in vitro during exponential cell growth
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(13). MT is mainly a cytoplasmic protein but it is also present in the nucleus during cell
proliferation and development (14). For example, MT has been detected in both the
nucleus and cytoplasm of human fetal hepatocytes, and the levels of MT increase with
gestational age (14). Cellular localization of MT appears to be cell cycle specific because
it peaks in the nucleus during S, and G2/M phases while maximal expression in the
cytoplasm occurs during G0 and G1 phases (13). MT is located mainly in the cytoplasm of
both human fetal and adult renal proximal tubule cells, but no correlation between
gestational age, level of MT or cellular localization in the kidney has been found,
suggesting that the distribution and expression on MT during development may be organ
specific (15). Thus, it would appear that nuclear localization of MT is either cell type
specific or characteristic of a particular proliferative state.
MT may also play a role as a zinc donor where required, such as in activating
zinc-finger transcription factors. The elevated concentrations of MT during proliferation
could be related to the increased demand for certain metals such as copper and zinc. A
number of MT inducers, such as glucocorticoids, lipopolysaccharides, steroids,
hormones, cytokines and tumor necrosis factors, can influence apoptosis in certain cells.
These experimental data suggest that MT plays a role during the apoptotic process. Cells
from MT-null mice have been found to be more susceptible to apoptosis after exposure to
tert-butyl hydroperoxide and anti cancer agents than normal MT-expressing cells (16). In
human, MT expression and reduction in the number of apoptotic cells have been
demonstrated in liver tumors, laryngeal hyperplastic lesion and squamous cell carcinoma
of the tongue (3). In summary over expression of MT appears to protect against apoptotic
cell death, while lack of MT increases cell susceptibility to apoptosis.
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With the involvement of MT in cell proliferation and apoptosis, it is not surprising
that the possible role and significance of MT in cancer has also received considerable
attention. The levels of MT expression have been investigated in a wild variety of tumors
(17). The MT content in tumors has been related to the proliferative states of the cells,
although it is also a function of the degree of maturation and differentiation of the tumor.
HOMEOSTASIS OF ESSENTIAL METALS
MT is thought to be involved in homeostasis of the essential metals, copper and
zinc, as it is the major zinc and copper binding protein in many tissues, and there is a
close relationship between tissue MT and zinc content (18, 3). The importance of zinc is
evident from its role as a major component of many enzymes and cell processes and from
the severe pathology observed in response to zinc deficiency in skin, neurological,
immune, and reproductive tissues (19). Mice over-expressing MT and also MT knockout
mice have been used as models to test this function of MT in vivo. For example,
transgenic mice with over-expressing MT-1 are more resistant to zinc deficiency. This
has been attributed to a larger pool of zinc bound to MT, thereby supporting the view that
MT is an important source of intracellular zinc.
A hypothesis was proposed that MT acts as a chaperone during synthesis and
modulation of metalloproteins. Metal requiring apoenzymes can abstract metals from MT
as demonstrated in vitro (20). Glutathione (GSH) can form a complex with MT; release
of zinc from MT mediated by interactions with GSH and Glutathione-disulfide (GSSG)
through S-thiolation (21). Evidence suggests that zinc released from MT is facilitated by
direct-coupled interaction of GSH and GSSG with MT via the thiolate ligands that confer
redox activation of zinc clusters resulting in oxido-reduction MT-Zn complexes. MT
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therefore may be acting as a sensor of the localized intracellular redox balance and may
itself influence redox balance through GSH and the known antioxidant properties of zinc.
It has been suggested that the control of cellular zinc distribution as a function of the
energy state of the cell is the long sought role of MT (22). In cells in culture, MT can
donate Cu to Cu-Zn superoxide dismutase and at least in vitro the Cu-MT interaction is
also under redox control (23). These facts support that MTs act as physiological
transporters of essential metals (such as Cu and Zn) and that this distribution is regulated
in redox-sensitive manner.
MT AS FREE RADICAL SCAVENGER
MT is induced by treatments like hyperoxia, ionizing radiations or cold exposure
and by substances like ethanol, paraquat, tert-butyl hydroperoxide that cause oxidative
stress. This suggests that MT may protect against reactive oxygen and nitrogen species.
Moreover, animal or cells in culture that are deficient in MT isoforms exhibit greater
susceptibility to oxidative stress caused by electrophilic mutagens, antineoplastic drugs,
nitric oxide as well as cadmium (24).
Over-expression of MT reduces the sensitivity of cells and tissues to free radical
damage and MT genes are transcriptionally activated in cells and tissues in response to
oxidative stress (25). The mechanism by which MT protects against oxidative stress is
suggested by the idea that the thiolate clusters of MT are primary targets for the reaction
of hydroxyl radicals. It is suggested that hydrogen peroxide, superoxide anions, and
peroxyl radicals interact with MT and result in oxidative modification of the protein, thus
suggesting that in vivo this may affect the capacity of the MT to bind metals. Free metals
(Cd and Zn) interact with in the cell membrane and interfere with iron redox reactions
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(by either competing for binding sites or causing structural changes which reduce
binding) thereby reducing the conversion of H2O2 to OH free radicals. A similar effect
was proposed where free radicals were thought to interact with the MT to release metals
and influence redox events. For example, Cu-MT enhances lipid peroxidation initiated by
organic hydro peroxides, suggesting that MT may act as an antioxidant or a pro-oxidant
depending on its association with metals (3).
ROLE OF MT IN METAL DETOXIFICATION
MT plays a major role in detoxification of metals like Cd2+ and Hg2+. After
exposure to various metals, there is a significant increase of MT in tissues such as kidney,
liver and intestine. Various cell types have also been shown to accumulate MT after
exposure to metals. Much of the information regarding metal toxicity has been obtained
from studying the toxic effects of Cd, which accumulates in body under normal
conditions. For example, tolerance to Cd following low dose pretreatment with
cadmium/zinc is directly related to the concentration of hepatic MT in rats (26, 27). Also,
Cd-resistant cell lines express very high levels of MT and these cells show increased
resistance to the toxic effects of several other metals.
The mechanism whereby metal-induced MT reduces the toxicity of metals may be
dependent on the metal and in addition they may be cell type specific. Studies using
transgenic mice that either over-express or are deficient in MT have provided further
insight in to the role that MT plays in the protection against metal toxicity. It has been
found that MT-1- over-expressing mice (which carry 56 copies MT-1 gene) are more
tolerant to hepatotoxicity and lethality caused by cadmium than control mice (28). And,
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mice with disrupted MT-1 and MT-2 genes (MT null mice) are more sensitive to
cadmium and mercury induced toxicity than control mice.
Induction of MT in the kidney protects against HgCl2- mediated nephrotoxicity.
The protective effect of MT against HgCl2 toxicity appears to be due to the MT binding
Hg in the cytosol (24).

MT EXPRESSION IN CANCER
The role of MTs in tumor biology can be looked at from 3 perspectives. The first
relates to the possible association of MT deficient states with sensitivity to carcinogenic
effects of heavy metals and other environmental carcinogens. Kondo and Woo examined
the effect of the loss of MT expression on the cytoxicity of anticancer agents and
mutagens using embryonic fibroblast cells from transgenic mice with targeted disruption
of MT-1 and MT-2 genes (29). These MT null cells expressed no detectable MT,
compared to wild type cells. MT null cells showed enhanced sensitivity to 2 hr exposure
to anticancer agents like cisplatin, melphalan, bleonycin and cytarabine. As a result of
this, the basal expression of the DNA damage response genes was elevated in MT null
cells compared to wild type cells. Anticancer drug treatment, however, did not produce a
greater increase in DNA damage response genes in MT null mice compared to wild type
cells. These results supported the hypothesis that endogenic MT levels affect the
sensitivity of cells to mutagens and anticancer drugs. The second perspective relates to
the possible role of MT over-expression in resistance of tumors to anti-cancer therapy.
The development of resistance to antineoplastic agents significantly restricts the efficacy
of these agents. Therefore, identification of the mechanisms of antineoplastic drug
resistance becomes a critical precursor to design new treatment strategies for cancer (30).
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The third perspective pertains to the demonstration that antibodies can be used to
immunochemically determine the expression of MT protein in archival paraffinembedded tissues. This allows retrospective studies of MT-3 expression status in a
variety of human tumors, showing an association of MT-3 over-expression with the type
and grade of tumor. For example, the E-9 antibody used in majority of studies for
detection of immunocytochemistry of tumor associated MT over-expression is well
characterized for specificity. The antibody is able to recognize both MT-1 and MT-2
isoforms (17). The expression of MT is correlated to the histological grade of the tumor;
with

the

well-differentiated,

low

Gleason

score

tumor

having

lower

MT

immunoreactivity than the poorly differentiated and high Gleason score tumors. In skin
carcinomas and melanomas, cervical carcinomas, acute lymphoblastic leukemia, MT-3
over-expression appears to be predominantly associated with the more malignant, highgrade tumors. In colonic and fibroblastic skin tumors, MT over-expression is associated
with more differentiated low-grade tumors. And in ductal breast carcinoma, MT overexpression has been related to locally invasive primary carcinoma of poor histological
type and grade.

EXPRESSION IN THE PROSTATE
MT1/2 IN THE PROSTATE
In a study to confirm the immunohistochemical localization of MT1/2 in the
human prostate using the commercially available E-9 antibody preparation, the general
finding was that MT immunoreactivity was localized in the cytoplasm and nucleus of
glandular epithelial cells. The immunoreactivity of MT was found to be most intense in
the peripheral zone, moderate in the transitional zone, and weak in the central zone;
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however, epithelial cells in all zones showed a large variability in MT staining intensity.
Marked immunostaining for MT was noted in areas with inflammation in granulomatous
chronic prostatitis. Increased intensity of E-9 MT immunostaining was also noted in the
areas of fibromuscular hypertrophy and in areas of chronic inflammation. In prostate
cancer, the expression of MT was correlated to tumor grade, and that MT has a wide
range of expression in the prostate cancer.
Human MT-1 protein can be theoretically produced from mRNA originating from
any combination of the several active MT-1 isoform genes, designated MT-1A, MT-1B,
MT-1E, MT-1F, MT-1G, MT-1H and MT-1X, while MT-2 protein is generated from a
single gene, designated MT-2A. It was found that expression of MT1/2 protein in the
normal human prostate is supported by transcription of mRNA originating from, at
minimum, the MT-1A, MT-1E, MT-1X and MT-2A genes. To determine if the
expression of the MT-1 and MT-2 isoforms are altered in prostate cancer, both when
compared to the expression pattern present in the normal tissue and between individual
cancers, the expression of the MT-1A, MT-1E, MT-1X and MT-2A genes was assessed
using total RNA isolated from paraffin embedded tissues from five cases of advanced
prostate cancer known to immunohistochemically overexpress the MT protein. The
finding that MT-1X mRNA was not expressed in any of the five prostate cancer
specimens demonstrated that MT isoforms expression is altered from the expression
pattern present in normal prostate tissues (31). The evidence that MT isoform gene
expression was altered among prostate tumors was provided by the finding that MT-1A
and MT-1E expression was present in some, but not all, of the five advanced cases of
prostate cancer. These findings suggest that the clinical significance of MT expression in
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human prostate cancer might be further defined if specific MT gene expression patterns
were known for individual tumors.
MT-3 IN THE PROSTATE
The study of MT-3 expression in the normal and cancerous human prostate can be
of significant importance for several reasons. First, MT-3 also has a high affinity for
binding with the metal, cadmium, and both occupational and environmental studies have
suggested a possible role of cadmium in prostate cancer etiology (32). Secondly, MT-1
and MT-2 family members have been shown to be expressed in epithelium of the normal
human prostate and they exhibit an altered pattern of expression in prostate cancer, with
expression correlating with Gleason score. Similarly MT-3 expression could also define a
pattern of expression correlating with the Gleason score. And lastly MT-3 has been
shown to posses a neuronal cell grown-inhibiting activity, which is not duplicated by the
other human MT classes (33). The demonstration that MT-3 is expressed in the human
prostate, prostate cancer and prostate cancer- derived cell lines, suggests additional
means by which prostate epithelial cell growth might be controlled.
Immunohistochemical localization of MT-3 was done by using an affinitypurified antibody against MT-3, which was generated using the dodecapeptide
GGEAAEAEAEKC (corresponding to MT-3 amino acid, 53-64, which contain the MT-3
unique amino acid insert) conjugated through the C-terminal cysteine sulfhydryl group to
keyhole limpet hemocyanine, using maleimidobenzoyl-N-hydroxysuccinimide ester (34).
The results observed in the normal prostate were, the acinar cells demonstrated no
immunoreactivity for MT-3 in normal glands from either the peripheral zone or central
zone. The basal cells in these acinar structures demonstrated weak cytoplasmic staining,
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with some instances of nuclear localization. In the fibromuscular stromal cells, very weak
staining was observed, particularly in the more compact stroma of the central zone. The
MT-3 immunoreactivity of the stroma was increased in areas of fibromuscular benign
prostatic hypertrophy. Moderate MT-3 immunoreactivity was observed in the
inflammatory cells, particularly the histiocytic cells with in granulomatous foci. In areas
of inflammation, increased staining of MT-3 was demonstrated in epithelial cells of the
acini and prostatic ducts.
RT-PCR analysis of MT-3 indicated that MT-3 mRNA is very vividly expressed
in the normal human prostate (below that of two commonly monitored housekeeping
genes, G3PDH and β-actin). Immunoblot determination of MT-3 protein content in six
normal human prostate specimens showed a large range of MT-3 expressions that varied
from a low of 4.0 pg MT/µg total protein to a high of 24.6 pg MT/µg total protein.
Increase in MT–3 immunoreactivity was demonstrated in prostatic intraepithelial
neoplasia (PIN) within the acinar cells. In prostatic adenocarcinoma, MT–3
immunostaining was positive within malignant cells; MT–3 expression was enhanced and
found to be highly variable in PIN lesion and primary prostate cancer cells. MT-3
immunoreactivity showed a correlation with the histological grade of the tumor, with the
well differentiated, low Gleason score tumors having lower MT–3 immunoreactivity than
the poorly differentiated and high Gleason score tumors.
Two of the commonly utilized prostate cancer cell lines, DU-145 and LNCaP,
were demonstrated to express mRNA for MT-3, while the PC-3 cell line demonstrated no
expression of MT–3. Analysis of MT–3 protein expression indicated that both the LNCaP
and DU-145 cells expressed the MT-3 protein in amounts similar to those found in the
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tissue specimens. The findings that MT-3 immunoreactivity elevated in PIN lesions and
in the primary prostate cancer cells suggested a possible dysregulation of MT-3
expression in prostate cancer. It is proposed that this will entail retrospective
determination if MT-3 is enhanced in all PIN lesion and primary cancers, and if the
degree of expression can be correlated to tumor grade, clinical stage or protein outcome
(34).

267-B1 NORMAL NEONATAL HUMAN PROSTATE CELL LINE
The cell line used in this study was obtained from the Biological Research Faculty
and Facility, Inc with the designation 267-B1. 267-B1 is an immortalized normal human
neonatal prostatic epithelial line isolated as a single colony of pRSV-T transfected NP-2s
cells (neonatal human prostatic epithelial cells). The cells were grown in P4-8F serum
free medium. This cell type was chosen because the prostate represents an organ that is
affected by the Cd2+ exposure in both animals and humans. The objective of this study is
to define the regulation of expression of the MT gene family in the normal human
prostate cell line, 267-B1 exposed to the metal, cadmium.
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MATERIALS AND METHODS
CELL CULTURE REAGENTS
267-B1 CELL LINE
This cell line was obtained from the Biological Research Faculty and Facility, Inc.
267-B1 is an immortalized normal human neonatal prostatic epithelial line isolated as a
single colony of pRSV-T transfected NP-2s cells (neonatal human prostatic epithelial
cells).
P4-8F SERUM FREE MEDIUM
This serum-free (ready-to-use) medium was designed to grow the immortalized
normal prostatic cell line 267-B1 and was obtained directly from Biological Research
Faculty & Facility, Inc., Ijamsville, MD. It consists of P4, a modified basal medium
PFMR4 without the trace element concentrate and with Ca2+ concentration reduced to
0.5mM, supplemented with 30nM H2SeO3 (Johnson Matthey Chemicals, Ltd.,
Hertfordshire, England), 5ng/ml epidermal growth factor (Collaborative Research),
5ug/ml insulin, 0.28uM hydrocortisone, 0.5uM phosphoethanolamine, 0.1nM cholera
toxin (Calbiochem), 250 ug/ml BSA (Sigma), and 0.5% BPE (bovine pituitary extract)
PHOSPHATE BUFFERED SALINE (1X PBS)
To make 5 liters of 1x PBS, 42.5 g of NaCl (Sigma, Cat No. S-9888) was
combined with 0.6 g Na2HPO4 (Fisher Scientific, Cat No. S-374) and 0.12 g NaH2PO4
(Fisher Scientific, Cat No. S-369) in a total volume of 5 liters of deionized water. PBS
was aliquoted into 500-ml bottles, autoclaved, and stored for up to one year at 4°C.
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267-B1 CELL CULTURE
The 267-B1 normal prostate cells were obtained from the Biological Research
Faculty and Facility, Inc. These cells were grown in T-75 flasks (Corning, Cat No.
430720). The growth surface of the T-75 flask was treated with FNC coating mixture, a
collagen matrix to promote cell attachment and subculture. Excess of the coating mixture
was discarded and the flasks were allowed to air dry. Confluent normal prostate cultures
were used in subculturing the cells. To passage the cells, media was removed from the
flask maintained and the flasks were rinsed with 7.5 ml of sterile PBS. The PBS washes
were discarded and the cells of each flask were treated with 3 ml of trypsin-EDTA
(Gibco-BRL, Cat No. 25300-062). The cells were trypsinized until the cells appeared
completely dissociated (approximately 5-10 min). The cell suspensions were collected in
a 15-ml conical tube and the flasks were rinsed with 9 ml of PBS. The PBS washes were
transferred to the tube containing the trypsinized cells. 1 ml of 5% Fetal Bovine Serum
was added to the cell suspension to stop the tryptic action. The tube was centrifuged for 5
min at 10,000 rpm. The supernatant was removed and the cell pellet was thoroughly
resuspended in 10 ml of complete serum-free medium. A 1-ml aliquot of the cell
suspension was transferred to a T-75 flask that was precoated with FNC coating Mix,
containing 14 ml of the P4-8F medium. The flasks were routinely subcultured (1:10 ratio)
unless stated otherwise. Subcultured flasks were fed with 15 ml of fresh medium 24 hr
following subculture and every 72 hr thereafter and maintained under standard conditions
of 37°C in a 5% CO2: 95% atmosphere.
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CELL GROWTH
Growth studies were initiated over a period of 10 days. Five 6-well plates were seeded at
a ratio of 20,000 cells/well. The cells were fed every 48 hrs and maintained at a constant
temperature of 37°C in a 5% CO2: 95% atmosphere. Cell counts were determined by the
automated counting of 4’, 6-diamidino-2phenylindole (DAPI)-stained nuclei of cells
fixed and processed at days 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 of cell growth. In this
procedure, the nuclear stain DAPI and Kontron KS 400 image analysis software (Kontron
Elektronik, Newport Beach, CA) was used. At the indicated time points, wells containing
the mono-layers were rinsed with phosphate-buffered saline (PBS), fixed for 15 min in
70% ethanol, rehydrated with PBS, and stained with 10µl DAPI (10µg/ml in PBS). For
analysis, each well was examined under epifluorescent illumination at 40× magnification
on a Zeiss Axiovert 35 (Carl Zeiss Inc., Thornwood, NY) linked to the computer with an
Optronics DEI 470CCD camera (Optronics, Goleta, CA) for each time point, a minimum
of 20 fields per well and three wells per data point were determined. The doubling time
for the 267-B1 normal prostate cells was calculated using the formula (ln2)/(slope × 24) =
time (hr) for doubling cell number. The slope was derived from a linear regression of
ln [cell number] plotted against number of days of cell growth.

CADMIUM EXPOSURE & RECOVERY
SET UP
Twelve 6-well plates were seeded at a 1:4 subculture ratio using serum-free 267B1 cultures. The growth surface was coated with FNC coating Mix prior to the seeding of
the cells. The cells were fed every 72 hr until the cells were confluent. The final feeding
came 24 hr prior to starting the experiment. Preliminary pilot studies were performed to
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determine the approximate concentrations of metal salt resulting in the 267-B1 prostate
cell toxicity over a 4-hr period of exposure and subsequent recovery of cells in serumfree growth medium for 48 hrs. The concentration selected for this experiment was 18µM
Cd as 80-85% of cells survived by the end of 48 hrs of the recovery phase. Confluent
267-B1 normal prostate cells were treated with this metal concentration and cell viability,
MT-mRNA and MT protein were determined at 0 hr, 1 hr, 2 hr, 4 hr exposure and then
the cells were recovered with normal medium after 4 hr, 8hr, 12hr, 16hr, 24 hr, 36hr and
48hr. A 24hr control was also determined. Experiment was conducted in triplicates.

TOTAL RNA ISOLATION AND RT-PCR
Total RNA was isolated according to the protocol supplied with TRI REAGENT
(Molecular Research Center, Inc., Cincinnati, OH) as described below.
RNA ISOLATION PROTOCOL
Medium was removed from the wells and 1ml of TRI Reagent was added to each
well. The resultant lysates were stored at room temperature for 5-10 minutes to
completely dissociate nucleoprotein complexes. Cell lysates were then passed several
times through a 1ml pipette to shear DNA, and transferred to an RNase free microfuge
tube. Cell lysates were immediately stored at –70oC. Samples were removed from the
- 70oC freezer and thawed at room temperature. Then 100µl of Bromochloropropane
(BCP-Cat No. BP-151) was added to each sample extract and vortexed well and left aside
for about 10 minutes. The samples are then centrifuged in a table-top counter for 10 min
at 14000 rmp at 4oC. The top layer (RNA) was transferred into an RNase free tube and
0.5ml isopropanol was added. The contents were mixed well and kept aside for 10 min
and centrifuged again at 14000 rmp at 40C. The resulting supernatant was removed and
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the left over RNA pellet was washed with 70% ethanol. The pellet was washed with
ethanol 2-3 times and then left to air dry. 40µl of water was later added to the dry pellet
and stored in –70oC immediately.
RNA QUANTITATION BY SPECTROPHOTOMETER
The concentration and purity of the samples was determined using
spectrophotometer scan in the UV region. The RNA sample was thawed and 3µl of RNA
was added to 97µl of 1mM RNase free phosphate buffer (pH 7.0). The spectrophotometer
cuvet was cleaned with dH2O and 100µl of RNase free phosphate buffer (blank) was
added. The absorbence was recorded at 260nm, 280nm, and the 260/280ratio obtained.
Phosphate buffer was removed and a second volume of 100µl-phosphate buffer was
added and absorbence recorded again. If the absorbence was the same, it was set as a
blank. If not, cuvet was cleaned and phosphate buffer added and absorbences recorded
again till they were the same. The blank was removed and the first sample of RNA was
added and absorbence recorded at 260nm, 280nm, and the 260/280ratio obtained.
Absorbence of all RNA samples was obtained in this manner. The RNA concentration
was calculated using the following equation.
RNA Concentration =Absorbance at 260nm X 40µg/mL X volume of the sample (0.1mL)
Volume of the RNA sample (3µL)
RT-PCR
Total RNA (0.1µg) was reverse transcribed using murine leukemia virus reverse
transcriptase (50 units) in 1X PCR buffer (50 mM KCl and 10 mM Tris-HCl, pH 8.3),
5 mM MgCl2, 20 units RNase inhibitor, 1 mM each of the dNTPs, and 2.5µM random
hexanucleotide primers. The samples were reverse transcribed for 20 min at 420C,
followed by 5 min denaturation step at 990C using a DNA thermocycler (Perkin-Elmer-
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Cetus 9600; Perkin Elmer, Foster City, CA). The reverse transcribed product was used
for PCR amplification using the AmpliTaq DNA polymerase enzyme (2.5units) (Perkin
Elmer) and the specific upstream and downstream primers at a concentration of 0.1µM
each. The primers for mRNA analysis were upper 5’CTCGAAATGGACCCCAA
CT3’ and lower 5’ATATCTTCGAGCAGGGCTGTC3’ yielding a 219-bp product for
MT-1A; upper 5’ GCTTGTCTTGGCTCCACA3’ and lower 5’AGCAAACCGGTCAGG
TCAGGTAGTTA3’ yielding a 287-bp product for MT-1B; upper 5’GCTTGTTCGTCTC
ACTGGTG3’ and lower 5’CAGGTTGTGCAGGTTGTTCT3’ yielding a 284-bp product
for MT-1E; upper 5’AGTCTCTCCTCGGCTTGC3’ and lower 5’ACATCTGGGAGAA
AGGTTGTC3’ yielding a 232-bp product for MT-1F; upper 5’CTTCTCGCTTGGGAA
CTCTA3’ and lower 5’AGGGGTCAAGATTGTAGCAAA3’ yielding a 309-bp product
for MT-1G; upper 5’CCTCTTCTCTTGTCGCTTGG3’ and lower 5’GCAAATGAGTCG
GAGTTGTAG3’ yielding a 315-bp product for MT-1H; upper 5’TCTCCTTGCCTCGA
AATGGAC3’ and lower 5’GGGCACACTTGGCACAGC3’ yielding a 151-bp product
for MT-1X; upper 5’CCGACTCTAGCCGCCTCTT3’ and lower 5’GTGGAAGTCGCG
TTCTTTACA3’ yielding a 259-bp product for MT-2A; upper 5’CCGTTCACCGCCTC
CAG3’ and lower 5’CACCAGCCACACTTCACCACA3’ yielding a 325-bp product for
MT-3; upper 5’CATGGACCCCAGGGAATGTGT3’ and lower 5’GGGGTGGGCACGA
TGGA3’ yielding a 213bp product for MT-4. Primers for glyceraldehyde 3-phosphate
dehydrogenase (G3PDH) mRNA were obtained commercially (Clontech, Palo Alto, CA).
The thermocycler was programmed to cycle at 950C for 2 min initial step, at 950C for 30
seconds and at 680C for 30 seconds with a final elongation step at 680C for 7 min.
Controls for each PCR included a no-template control where water was added instead of
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the RNA and a no-reverse-transcriptase control where water was added instead of the
enzyme. Samples were removed at appropriate intervals between 22 and 40 cycles to
ensure that the reaction remained in the linear region. The final PCR products were
electrophoresed on 2% agarose gels containing EtBr along with DNA markers. The
intensity (integrated optical density, IOD) of the PCR product bands was determined on a
Dell workstation configured with Kontron KS 400 image analysis software (Zeiss,
Thornwood, NY).

PROTEIN EXTRACTION
Cells were washed twice with phosphate-buffered saline (PBS) and then lysed in
400uL sodium dodecal sulfate buffer and the cell lysate was stored in tubes in -700C.

PROTEIN QUANTITATION
THE

ELISA

TOTAL

PROTEIN

ASSAY

USING

THE

BCA

COPPER

REDUCTION METHOD
Protein concentrations were determined by the BCA protein assay (Pierce
Chemical Co., Rockford, IL). 0.5, 1, 2, 4, 6, 8, 10 µg BSA were chosen as the standards
for this assay. 100uL of each of these standards was made. In a flat bottom 96 well plate,
5ul of SDS lysis buffer and 10µL of water was added to the first two “blank” wells. 5uL
of SDS lysis buffer and 10µL of standard was added to the corresponding standards
wells. 10uL of water and 5µL of SDS samples was added to corresponding sample wells.
200µL of BCA reagent (50:1 BCA solution: CuSO4) was added to each well and
incubated at 370C for one hr. The plate was scanned using a Dynatech MR 5000 plate
reader (Dynatech Inc., Guernsey Channel Island).
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Final protein concentration = Protein concentration obtained in the print out
Volume of sample (5µL)

MT PROTEIN DETERMINATION
MT protein was detected by immunoblotting using a mouse anti-horse antibody
(DAKO-MT, E9, Dako, Carpinteria, CA) as the primary antibody. This antibody detects
both the MT-1 and MT-2 isoforms, and the product detected is referred to as MT-1/2 in
this report. MT-3 protein was detected by immunoblotting using an antibody against
human MT-3 as the primary antibody.
Aliquots of 3µg total protein were diluted to 75µl in SDS buffer and mixed with
75µl of 3% glutaraldehyde to enhance the detection of MT. 100µl of this mixture (2µg of
total protein) were applied to a dot blot apparatus with polyvinylidine difluoride
membrane. Samples were allowed to flow through the apparatus by gravity, followed by
two 100µl PBS washes. After blocking with 10% skim milk in PBS for MT1/2 protein,
the membrane was washed three times in PBS for 10 min. The membrane was soaked in
the primary antibody (1:100 dilution, 1% BSA in PBS) for 2 hrs. The membrane was
washed three times in PBS for 10 min each before anti mouse alkaline phosphatase
conjugated secondary antibody (Promega, Madison, WI) was added (1:500 dilution, 0.4%
BSA in PBS). The membrane was washed again three times with PBS for 10 min each
and then washed with alkaline phosphate buffer for 10 min. Antibody complexes were
then visualized using the alkaline phosphate kit III (Vector laboratories, Burlingame, CA)
by adding 10 drops each of tubes labeled 1, 2, & 3, respectively. Rabbit liver Cd/Zn
metallothionine-1 (Sigma Chemical Co., St. Louis, MO) was applied to each blot to
generate standard curves. MT-1/2 protein was quantified by comparing the optical
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density of the sample dots to that of the standard MT curve, using image analysis
software (KS- 400, Kontron, Zeiss, Thornwood, NY). This assay has detection limits in
the range of 0.1-0.5 ng MT-1/2 protein.
MT-3 protein was detected by immunoblotting using an antibody against human
MT-3 as the primary antibody. Aliquots of 3µg total protein were diluted to 75µl in SDS
buffer and mixed with 75µl of 3% glutaraldehyde to enhance the detection of MT. 100µl
of this mixture (2µg of total protein) were applied to a dot blot apparatus with
polyvinylidine difluoride membrane. Samples were allowed to flow through the
apparatus by gravity, followed by two 100µl PBS washes. The membrane is blocked with
3% BSA in PBS then soaked in primary antibody (4.5µg/ml, 1% BSA in PBS) for 2 hrs.
The membrane was washed three times in PBS for 10 min each and then soaked in
alkaline phosphatase-conjugated secondary antibody (Promega, Madison, WI) at a 1:500
dilution. Antibody complexes were then visualized using the alkaline phosphate kit III
(Vector laboratories, Burlingame, CA) by adding 10 drops each of tubes labeled 1, 2, &
3, respectively. Standard curves of the synthetic peptide (GGEAAEAEAEKC)
conjugated to BSA were applied to each blot. MT-3 protein was quantified by comparing
the optical density of the sample dots to the standard MT-3 curve, using image analysis
software (KS- 400, Kontron, Zeiss, Thornwood, NY). This assay has detection limits in
the range of 0.5-2 pg MT-3 protein.
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RESULTS
267-B1 CELL GROWTH
The growth rate of the 267-B1 cells was accomplished by subculturing at 20,000
cells/well in a six-well plate and monitored the growth by the automated counting of
DAPI-staining nuclei from day 1 to day 10. The increase in cell number is depicted in
Figure 2. From this data, the doubling time was calculated to be 38.33 hours similar to a
doubling time of 35.5±2.5 hours in PC-3, prostate cancer cells.

MT-mRNA AND PROTEIN EXPRESSION IN THE 267-B1 CELL
LINE
MT-1A: The initial experimental goal was to define the basal level of MT-1A mRNA
expression in normal human prostate cells not exposed to any metals. The mRNA
expression for the housekeeping gene G3PDH was used as a comparison for MT-1A
mRNA expression. The reactions were stopped and samples removed for analysis at 30,
35, and 40 PCR cycles. No expression of MT-1A was demonstrated under basal
conditions even at 40 PCR cycles. This is in contrast to G3PDH, where the same total
RNA input demonstrated a reaction product corresponding to G3PDH mRNA at 30 PCR
cycles (Fig 3). These findings indicate that 267-B1 cells have no basal expression of MT1A mRNA. The effect of Cd2+ on the expression MT-1A mRNA was also determined on
these cells after maintaining in serum-free medium following exposure to 18µM
cadmium for 4 hours (Fig 4). An appearance of MT-1A mRNA was observed between 2
hour exposure and 16 hour recovery.
MT-1E: The basal expression of MT-1E mRNA was evaluated using the total RNA
samples described above. Results demonstrated that basal expression of MT-1E mRNA
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was evident in 30 PCR cycles for the 267-B1 cell isolates. Product intensities were about
one-half of that noted for the G3PDH housekeeping gene at an identical cycle number
(Fig 3). The effect of cadmium on the expression of MT-1E mRNA was also determined
for the 267-B1 cell isolates. Results showed three fold increase in induction of MT-1E
mRNA upon exposure to cadmium and dropped back to basal levels in the recovery
phase where the cells were maintained in the serum-free normal medium. (Cd2+ free) (Fig
5).
MT-1F: The basal level of MT-1F mRNA expression was also assessed in the 267-B1
cells. MT-1F mRNA, like MT-1A mRNA, was shown to be a rare transcript in the 267B1 cells even at 40 PCR cycles. This is in contrast to G3PDH where the same total RNA
input demonstrated a convincing reaction product corresponding to G3PDH mRNA at 30
PCR cycles (Fig 3). The MT-1F mRNA expression was determined for cells maintained
in serum-free medium following exposure to 18µM Cd2+ for 4 hrs. Results showed an
appearance of the MT-1F mRNA expression which plateaued at 4 hr of exposure and 4 hr
of recovery following the exposure to the metal at which time it gradually falls back to
nearly undetectable levels (Fig 6).
MT-1G: No basal expression of MT-1G mRNA was demonstrated under basal
conditions even at 40 PCR cycles. This is again in contrast to G3PDH, where the same
total RNA input demonstrated a convincing reaction product corresponding to G3PDH
mRNA at 30 PCR cycles (Fig 3). The effect of Cd2+ on MT-1G mRNA expression was
also determined, and the results showed a considerable increase in expression especially
at 4 hr exposure. Expression fell back to undetectable levels before the recovery phase
was completed (Fig 7).
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MT-1X: Basal expression of MT-1X mRNA was evident at 30 PCR cycles, about onethird to that noted for G3PDH (Fig 3). The effect of Cd2+ on the MT-1X mRNA
expression was determined and results revealed a near two fold induction in mRNA at
only 4 hr exposure 4 hr recovery (Fig 8).
MT-2A: Basal expression of MT-2A mRNA was evident at 25 PCR cycles and
prominent at 30 PCR cycles. This expression is similar to expression for G3PDH for the
267-B1 cells (Fig 3). The effect of Cd2+ on Mt-2A mRNA showed a slight increase in the
induction of MT-2A mRNA expression, regaining back to basal levels in the recovery
phase where the cells were maintained in the normal medium for next 48 hours (Fig 9).
MT-3: Basal expression of MT-3 mRNA was evaluated for the 267-B1 cells using the
total RNA samples. Results showed that the basal expression of MT-3 mRNA was very
little even at 40 PCR cycles (Fig 3). This was in contrast to G3PDH, where the same total
RNA input demonstrated a convincing reaction product corresponding to G3PDH mRNA
at 30 PCR cycles. In contrast to the results for other isoforms described above, exposure
to Cd2+ did not induce any increase in the accumulation of MT-3 mRNA. These results
indicated that MT-3 mRNA contributes very little towards total MT mRNA in 267-B1
cells and that the level of expression of MT-3 is not increased due to Cd2+ exposure (Fig
10).
Determination of MT-1/2 protein content in the 267-B1 cell line was done by
immunoblotting a mouse anti-horse antibody (DAKO-MT, E9, Dako, Capinteria, CA) as
the primary antibody. This antibody detects both the MT-1 and MT-2 isoforms, and the
product detected is referred to as MT1/2. The basal level of MT1/2 protein in the 267-B1
cell line was detected to be 3.20±0.17 ng/µg protein. Upon exposure of cells to Cd2+ for 4
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hours, followed by 48 hours of recovery phase in the normal medium, the results
demonstrated an increase in protein content with 16.11±2.58 ng/µg protein at 12 hr of
recovery and regaining back to basal levels by 48 hours of recovery. Results show that
MT1/2 protein in 267-B1 cells is supported by transcription of mRNA primarily from
MT-1E, MT-1X, and MT-2A and supported minorly by transcription of mRNA from
MT-1A, and MT-1F (Fig 11).
MT-3 protein was detected by immunoblotting using an antibody against human
MT-3 as the primary antibody. No MT-3 protein at the basal level was detected in the
267-B1 cell line (Fig 3). Upon exposure of cells to Cd2+ for 4 hours, followed by 48hours
of recovery phase in normal medium, the results no significant MT-3 protein level as a
result of Cd2+ exposure (Fig 10).
MT-1B, MT-1H AND MT-4: Basal expression and metal-induced expression of mRNA
for the MT-1B, MT-1H and MT-4 genes were also determined using the above RNA
samples. No expression of MT-1B, MT-1H, and MT-4 mRNA was demonstrated under
basal conditions or after treatment with Cd2+.
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Figure 1 Phase-contrast photomicrograph of 267-B1 cells. Confluent monolayer of
267-B1 normal neonatal prostate cells maintained in P4-8F serum-free growth medium.
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Figure 2 Growth curve of 267-B1 cells. Confluent monolayer of 267-B1 normal
neonatal prostate cells maintained in P4-8F serum-free growth medium.
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Figure 3 Basal MT gene expression determined by RT-PCR using total RNA from
267-B1 cells. Total RNA was purified from the 267-B1 cells and subjected to RT-PCR
using primers specific for G3PDH, MT-1A, MT-1B, MT-1E, MT-1F, MT-1G, MT-1H,
MT-1X, MT-2A, MT-3, and MT-4. The reactions were sampled at 25, 30, 35, 40 cycles
and the products visualized on 2% agarose gel containing 0.25µg per ml ethidium
bromide.

28

Figure 4 Expression of MT-1A in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1A (40 cycles). Gel shows gene expression at various time points during exposure
and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for MT-1A gene
expression.
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Figure 5 Expression of MT-1E in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1E (30 cycles). Gel shows gene expression at various time points during exposure
and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for MT-1E gene
expression.
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Figure 6 Expression of MT-1F in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1F (40 cycles). Gel shows gene expression at various time points during exposure
and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for MT-1F gene
expression.
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Figure 7 Expression of MT-1G in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1G (40 cycles). Gel shows gene expression at various time points during exposure
and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for MT-1G gene
expression.
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Figure 8 Expression of MT-1X in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-1X (40 cycles). Gel shows gene expression at various time points during exposure
and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for MT-1X gene
expression.
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Figure 9 Expression of MT-2A in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-2A (25 cycles). Gel shows gene expression at various time points during exposure
and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for MT-2A gene
expression.
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Figure 10 Expression of MT-3 in 267-B1 cell line maintained in serum-free growth
medium following exposure to 18mM cadmium for four hours. A) RT-PCR analysis
of MT-3 (40 cycles). Gel shows gene expression at various time points during exposure
and recovery from exposure to cadmium. B) Mean IOD values (+SEM) for MT-3 gene
expression.

35

Figure 11 Expression of MT-1/2 protein in 267-B1 cell line maintained in serum-free
growth medium following exposure to 18mM cadmium for four hours. IOD of bands
represent MT1/2 protein.
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DISCUSSION
The objective of this study was to characterize the basal level expression of all the
MT-isoforms in the 267-B1 normal prostate cell line and also to observe the expression
of the MT- isoforms in response to cadmium exposure. An analysis of basal level MT
mRNA expression in the 267-B1 cells demonstrated the expression of mRNA
representing the MT-1E, MT-1X, MT-2A, and MT-3 genes. The MT-3 mRNA
expression levels were lower than the rest of the isoforms expressed. The basal levels of
the MT-1E, MT-1X, and MT-2A isoforms were similar to the expression of the G3PDH
house-keeping gene, where as mRNA for MT-1A, MT-1B, MT-1F, MT-1G, MT-1H and
MT-4 showed no basal expression. An analysis of MT mRNA expression in human
proximal tubule cells demonstrated the expression of mRNA representing MT-1E, MT1X, MT-2A, and MT-3 as the most common transcripts, having expression levels similar
to the G3PDH house keeping gene, while mRNA for the MT-1A and MT-1F genes were
demonstrated to be less abundant (35). Another study done by Garrett and Sens M.A et al
indicated the basal expression of MT-1A, MT-1E, MT-1F, MT-1X, MT-2A and MT-3
genes in the normal human prostate (31, 34). The expression of mRNA in the normal
human prostate tissue for MT-1X and MT-2A isoforms had the highest expression when
compared to MT-1A, MT-1E, and MT-1F (31). The results for MT-3 mRNA genes in the
normal human prostate indicated that the level of expression, while not rare, was below
that of the 2 commonly monitored housekeeping genes (34). Comparing the findings
between the human proximal tubule cells, the normal human prostate tissue and the 267B1 cells, it can be said that the 267-B1 cells retained the expected pattern of MT mRNA
expression.
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Determination of MT-1/2 protein content of the 267-B1 cells by immunoblot was
observed to be 3.20 ± 0.17 ng MT/µg total protein. These protein levels are close to the
levels obtained in the six normal prostate tissue specimens which demonstrated to have a
range of MT-1/2 expression that varied from a low of 2.99 ± 0.19 ng MT/µg total protein
to a high of 8.71 ± 0.13 ng MT/µg total protein (31). There was no MT-3 protein content
in the 267-B1cells compared to the MT-3 protein expression in the normal prostate tissue
which had a range of expression varying from a low of 4.0 pg MT/µg total protein to a
high of 24.6 pg MT/µg total protein (34).
We also observed the effect of cadmium on the expression of the different MTisoforms in the 267-B1 cells by exposing the cells to 18µM Cd2+ for four hours followed
by rescue in normal serum free growth medium. In total RNA preparation from 267-B1
cells exposed to Cd2+, mRNA for the MT-1E showed a three fold induction, mRNA for
the MT-1X showed a two fold induction, MT-1A, MT-1F, MT-1G genes were
demonstrated to have a considerable increase in induction, while the mRNA for MT-2A
gene compared to the others isoforms showed only a slight increase in expression. This
difference in induction of MT-2A can be compared with the findings in a previous study
of human proximal tubule cells, where it was shown that human proximal tubule cells
exposed to Cd2+ had no corresponding increase in the amount of MT-2A mRNA (37). In
contrast to the increase in mRNA for only the MT-1A and MT-1E genes in the human
proximal tubule cells exposed to Cd2+, the 267-B1 cells showed a considerable Cd2+
induction for MT-1A, MT-1E, MT-1F, and MT-1G genes. All four isoforms showed a
gradual increase in mRNA expression with the highest induction being at 4 hr exposure
and recovering back to the basal levels within 24 hr after rescuing the cells in the normal
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serum free growth medium. The expression of the MT-1/2 protein content in the 267-B1
cells showed a gradual increase upon Cd2+ exposure, but more protein accumulation was
seen in the following 16 hr recovery phase with 16.11±2.58 ng MT/µg total protein being
the highest level of protein expression.
The effect of Cd2+ on the expression of MT-3 mRNA was also determined for the 267-B1
cells. Results showed no increase in the level of MT-3 mRNA expression. MT-3
expression is reported to be mainly in the brain and findings from a study demonstrate
that MT-3 mRNA levels in the testis, epididymis, prostate and tongue were only 22% of
those in the brain (36). It was also shown that MT-3 gene was not inducible by CdCl2 in
rat testis and prostate. In human, relative MT-3 mRNA levels were lower than those
found in the rat. However, in contrast, induction of MT-3 mRNA was shown to occur in
cultures of the human proximal tubule cells when exposed to Cd2+ and Zn2+ (10). Studies
also indicate that MT-3 immunoreactivity is elevated in PIN lesions and in primary
prostate cancer cells suggesting a possible dysregulation of MT-3 expression in prostate
cancer. While DU-145 and LNCaP prostate cancer cell lines were demonstrated to
express mRNA for MT-3, the PC-3 cell line demonstrated no expression for MT-3. This
variable nature of MT-3 expression suggests an area of further study.
In conclusion, the patterns of induction are quite different between MT-1, MT-2
and MT-3 gene family and also different between organs and tissues. Further
determination of the expression levels of individual MT-1 and MT-2 isoform- specific
proteins would allow the determination of the relative contributions of the MT proteins.
Newly developed MT-null cells can be used to conduct transfections by expressing
vectors containing each human MT isoforms- specific gene, and study the expression
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levels and functional properties of each specific MT isoforms protein. Furthermore, this
267-B1 cell line would serve as an excellent recipient of stable trasfection of a vector
over-expressing the MT-3 gene to model the consequences of MT-3 over-expression seen
in prostate cancer. This cell line also serves as a non- neoplastic control for the PC-3
prostate cancer cell line, which is being extensively studied in this laboratory.

40

APPENDIX
REAGENTS USED FOR PROTEIN CELL EXTRACTS
2% SDS BUFFER (50mM Tris, pH 6.8; 2% w/v SDS).
1 gram of Sodium Dodecal Sulfate (SDS) is combined with 50ml of 50mM Tris Cl
(pH=6.8) in a tube and placed on a rocker for at least one hour until SDS is completely
dissolved.
PRIMARY ANTIBODY (1:100) FOR MT-1/2 MONOCLONAL MOUSE ANTIHORSE MT (DAKO-MT, E-9)
•

MT Ab, E9 from DAKO – (1:100)

•

BSA (1%)

•

NaN3 (0.02%)

•

PBS to 45ml

SECONDARY ANTIBODY (1:500) FOR MT-1/2 ANTI MOUSE AB IgG
(Promega)
•

Anti-mouse Ab IgG – (1:500)

•

BSA (0.4%)

•

NaN3 (0.02%)

•

PBS to 45ml

PRIMARY ANTIBODY (1:400) FOR MT-3
•

MT-3 Ab – (1:400 of 0.5µg/ml)

•

BSA (2%)

•

NaN3 (0.02%)

•

PBS to 45ml
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SECONDARY ANTIBODY (1:500) ANTI-RABBIT
•

Anti-rabbit Ab – (1:500)

•

BSA (0.4%)

•

NaN3 (0.02%)

•

PBS to 45ml
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RESEARCH EXPERIENCE:
Characterization of Metallothionein gene
West Virginia University, Department of Urology
•
•
•

Dec 2000 – Present
Characterized mRNA and protein expression of the metallothionine gene in a normal prostate
cell line in response to cadmium.
Techniques used in this project include Cell culture, RT-PCR, Gel electrophoresis, Immunoblotting analysis of Proteins.
RT-PCR bands and MT protein was quantified using Kontron KS 400 image analysis
software.

Characterization of Heat-shock Protein
West Virginia University, Department of Urology
Jan 2000 – Dec 2000
• Characterized the mRNA and protein expression of heat shock proteins (Hsp 90α and
Hsp90β) in Human Kidney Proximal tubule cells in response to cadmium through RT-PCR
and Western Blotting respectively.

Children’s Personality Profile
Osmania University, India. Department of Psychology.
Jan 1998
• Established personality profile of children under the age group of 11 years using various
personality and analytical tests.

Association of Leukemia with blood groups
MNN Cancer Center, India.
Jan
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• Investigated the symptoms and evaluated statistically the correlation between the incidence of
leukemia and blood groups.
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Jan 2000 – Present
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• Characterized the expression of metallothionine gene in response to cadmium.
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Gel Electrophoresis
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Kontron KS 400 image analysis software
Microsoft Word
Microsoft Excel
Microsoft PowerPoint
Adobe Photo Shop 5.1
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